http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16182187

Outgoing Links

Predicate Object
contentType Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 1739
issn 0923-7534
issueIdentifier 9
pageRange 1733-1739
publicationName Annals of oncology : official journal of the European Society for Medical Oncology
startingPage 1733
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_ac6a16677cd6e7190444cc5f4fe4a25f
bibliographicCitation Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Ann Oncol. 2016 Sep;27(9):1733–9. doi: 10.1093/annonc/mdw236. PMID: 27287207.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_320e80c959c83f20aad005c7bf1485f6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5cae76b5993756864f43fbd27907164e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e68f84afc2b60243729d418a57b0d50
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67f8ef82822bec7c19b8c0da787b9c2a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_188f396bf0245d892b01b32ad572790f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_19c1339ed0c1b6769ab0c86ebdfc940f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c48b53ed9b78d4c345efe888914e7d8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53adede0ed8bed887dd0fb66cd93c1ac
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9deca99dd1e8b1d8d280d849b264bead
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_baacbed1ea4825a0ed82eee4c5159625
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db69f92d39d453e16e5d9a694b6bceba
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e27ad7d070230f9c6387e2ec5f971ad0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4437b91055437c047c3215384d89817
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_609967e5b455c41c533371cf349c3c8d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e911c8646c0dce96acea088216e61a31
date 201609
identifier https://doi.org/10.1093/annonc/mdw236
https://pubmed.ncbi.nlm.nih.gov/27287207
isPartOf https://portal.issn.org/resource/ISSN/0923-7534
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
discusses http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0443627
http://id.nlm.nih.gov/mesh/M0026156
http://id.nlm.nih.gov/mesh/M0015422
http://id.nlm.nih.gov/mesh/M0017026
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D017239Q000008
http://id.nlm.nih.gov/mesh/D010051Q000188
http://id.nlm.nih.gov/mesh/D000068258Q000008
http://id.nlm.nih.gov/mesh/D010984Q000008
hasSubjectTerm http://id.nlm.nih.gov/mesh/D061067Q000008
http://id.nlm.nih.gov/mesh/D019008Q000187
http://id.nlm.nih.gov/mesh/D061067Q000009
http://id.nlm.nih.gov/mesh/D017239Q000009
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D010051Q000473
http://id.nlm.nih.gov/mesh/D010984Q000009
http://id.nlm.nih.gov/mesh/D009944Q000008
http://id.nlm.nih.gov/mesh/D000068258Q000009
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D011379
http://id.nlm.nih.gov/mesh/D000971Q000008
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D018572
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9227
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4fb3b68e84149f91bcfd0102f95d3731
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6977

Showing number of triples: 1 to 63 of 63.